Trial Profile

A Phase 1b, Open-label, Dose-Finding Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Subjects With Newly Diagnosed Glioblastoma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 29 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trotabresib (Primary) ; Temozolomide
Indications Glioblastoma
Focus Adverse reactions; Therapeutic Use
Sponsors Celgene Corporation

Most Recent Events

26 Jul 2024 Status changed from active, no longer recruiting to discontinued as Business objectives have changed.
03 Jul 2024 Planned primary completion date changed from 12 May 2024 to 5 Jul 2024.
09 Nov 2023 Planned End Date changed from 5 Mar 2025 to 15 May 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com